Read that bit about CEY:http://www.aspecthuntley.com.au/af/marketdatastories?xsl-story=aust&xtm-licensee=newsletters
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress